Aquestive Therapeutics, Inc.
AQST
$2.87
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -12.37% | -32.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.37% | -32.62% | |||
| Cost of Revenue | 1.87% | -1.97% | |||
| Gross Profit | -19.31% | -41.53% | |||
| SG&A Expenses | 32.02% | 6.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.55% | 8.92% | |||
| Operating Income | -63.80% | -15,172.73% | |||
| Income Before Tax | -48.31% | -319.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -48.19% | -319.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -48.19% | -319.27% | |||
| EBIT | -63.80% | -15,172.73% | |||
| EBITDA | -64.91% | -3,227.31% | |||
| EPS Basic | -47.94% | -318.54% | |||
| Normalized Basic EPS | -37.72% | -170.55% | |||
| EPS Diluted | -43.85% | -330.46% | |||
| Normalized Diluted EPS | -37.72% | -170.55% | |||
| Average Basic Shares Outstanding | 0.13% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||